About: Pharmacological treatments of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacological treatments of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pharmacological treatments of COVID-19
Creator	Uk, Ghaleno, Hassan Habtemariam, Solomon Mojtahedzadeh, Mojataba Safdari, Mohammadreza Sahebnasagh, Adeleh Arasteh, Omid Avan, Razieh Faramarzi, Fatemeh Hassan, · Khataminia, Masoud Negarandeh, Reza Omid, · Sadremomtaz, Afsaneh Saghafi, Fatemeh Tanzifi, Asal Ghaleno, Rezai Habtemariam@herbalanalysis, Khoshi, · Masoud Khataminia, · Safdari, · Saghafi, ·
Source	Medline; PMC
abstract	The viral infection due to the new coronavirus or coronavirus disease 2019 (COVID-19), which was reported for the first time in December 2019, was named by the World Health Organization (WHO) as Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV2), because of the very similar genome and also its related symptoms to SARS-CoV1. The ongoing COVID-19 pandemic with significant mortality, morbidity, and socioeconomic impact is considered by the WHO as a global public health emergency. Since there is no specific treatment available for SARS-CoV2 infection, and or COVID-19, several clinical and sub-clinical studies are currently undertaken to find a gold-standard therapeutic regimen with high efficacy and low side effect. Based on the published scientific evidence published to date, we summarized herein the effects of different potential therapies and up-to-date clinical trials. The review is intended to help readers aware of potentially effective COVID-19 treatment and provide useful references for future studies. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s43440-020-00152-9) contains supplementary material, which is available to authorized users.
has issue date	2020-08-20(xsd:dateTime)
bibo:doi	10.1007/s43440-020-00152-9
bibo:pmid	32816200
has license	no-cc
sha1sum (hex)	861d3fa5a2ce546ca50edda9cfb977a47e7dfcd3
schema:url	https://doi.org/10.1007/s43440-020-00152-9
resource representing a document's title	Pharmacological treatments of COVID-19
has PubMed Central identifier	PMC7439639
has PubMed identifier	32816200
schema:publication	Pharmacol Rep
resource representing a document's body	covid:861d3fa5a2ce546ca50edda9cfb977a47e7dfcd3#body_text
is schema:about of	named entity 'potential' named entity '2019' named entity 'THERAPIES' named entity 'COV1' named entity 'AWARE' named entity 'SIDE EFFECT' named entity 'THERAPEUTIC REGIMEN' named entity 'NEW' named entity 'STUDIES' named entity 'PUBLISHED' named entity 'DUE TO' named entity 'CLINICAL' named entity 'EMERGENCY' named entity 'SIMILAR' named entity 'SARS-COV2 INFECTION' named entity 'COVID-19 PANDEMIC' named entity 'DATE' named entity 'CONSIDERED' named entity 'STANDARD' named entity 'IMPACT' named entity 'COVID-19' named entity 'PROVIDE' named entity 'DECEMBER' named entity 'TIME' named entity 'DIFFERENT' named entity 'GOLD' named entity 'time' named entity 'infection' named entity 'COVID-19' named entity 'public health emergency' named entity 'socioeconomic' named entity 'therapies' named entity 'Since' named entity 'socioeconomic' named entity 'global public health' named entity 'infection' named entity 'scientific evidence' named entity 'Severe Acute Respiratory Syndrome' named entity 'morbidity' named entity 'chain termination' named entity 'virological' named entity 'SARS-CoV2' named entity 'coronavirus' named entity 'thalidomide' named entity 'helicase' named entity 'host cell' named entity 'pneumonia' named entity 'ribavirin' named entity 'levamisole' named entity 'clinical evidence' named entity 'SARS-CoV2' named entity 'pneumonia' named entity 'fever' named entity 'SARS-CoV-2' named entity 'coronavirus' named entity 'synergistic' named entity 'SARS-CoV2' named entity 'recombinant' named entity 'antiviral' named entity 'SARS-CoV2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software